-
Brepocitinib (PF-06700841) is a drug
which acts as a dual
inhibitor of JAK1 and TYK2, and was
developed for the
treatment of
plaque psoriasis. Deucravacitinib...
-
between Roivant and Pfizer, in
which Pfizer licensed oral and
topical brepocitinib's global development rights and US and ****an
commercial rights to Priovant...
-
various autoimmune inflammatory conditions,
primarily plaque psoriasis.
Brepocitinib Deucravacitinib Martin G (February 2023). "Novel
Therapies in Plaque...
-
Peeva E,
Forman S,
Moiin A,
Khattri S,
Porter ML, et al. (March 2024). "
Brepocitinib, Zimlovisertib, and
Ropsacitinib in
Hidradenitis Suppurativa". NEJM Evidence...
-
activity relationship of may be
found in the
article on JAK3 inhibitors.
Brepocitinib (PF-06700841), dual JAK1/TYK2
inhibitor for
plaque psoriasis. Cerdulatinib...
-
Zhang N, Del Duca E,
Estrada Y, et al. (April 2022). "Ritlecitinib and
brepocitinib demonstrate significant improvement in
scalp alopecia areata biomarkers"...
